Prevention of cancer cachexia by pyrrolidine dithiocarbamate (PDTC) in colon 26 tumor-bearing mice

Journal of Parenteral and Enteral Nutrition

Volumn 31, Issue 1, 2007, Pages 18-25

  Nai, Yong Jun ^a   Jiang, Zhi Wei ^a,b   Wang, Zhi Ming ^a   Li, Ning ^a   Li, Jie Shou ^a  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; PYRROLIDINE DITHIOCARBAMATE;

ALBUMIN BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CACHEXIA; CANCER CACHEXIA; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE TIME EFFECT RELATION; DRUG EFFECT; EPIDIDYMIS FAT; FOOD INTAKE; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; IMMUNOMODULATION; MALE; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIOXIDANTS; CACHEXIA; COLONIC NEOPLASMS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; INJECTIONS, INTRAPERITONEAL; INTERLEUKIN-6; MALE; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NF-KAPPA B; PYRROLIDINES; RANDOM ALLOCATION; THIOCARBAMATES; WEIGHT LOSS;

MURINAE;

EID: 33845945738     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/014860710703100118     Document Type: Article

References (43)

1. Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer. 2002;2:862-871.
2. Tisdale MJ. Pathogenesis of cancer cachexia. J Support Oncol. 2003;1:159-168.
3. Costelli P, Carbo N, Tessitore L, et al. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model. J Clin Invest. 1993;92:2783-2789.
4. Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest. 1992;89:1681-1684.
5. Kuroda K, Horiguchi Y, Nakashima J, et al. Prevention of cancer cachexia by a novel nuclear factor κB inhibitor in prostate cancer. Clin Cancer Res. 2005;11:5590-5594.
6. Gelin J, Moldawer LL, Lonnroth C, Sherry B, Chizzonite R, Lundholm K. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res. 1991;51:415-421.
7. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996;379:739-742.
8. Matthys P, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer. 1991;49:77-82.
9. O'Riordain MG, Falconer JS, Maingay J, Fearon KC, Ross JA. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism. Int J Oncol. 1999;15:823-827.
10. Darling G, Fraker DL, Jensen JC, Gorschboth CM, Norton JA. Cachectic effects of recombinant human tumor necrosis factor in rats. Cancer Res. 1990;50:4008-4013.
11. Greenberg AS, Nordan RP, McIntosh J, Calvo JC, Scow RO, Jablohs D. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res. 1992;52:4113-4116.
12. Fujita J, Tsujinaka T, Yano M, et al. Anti-interleukin-6 receptor antibody prevents muscle atrophy in colon-26 adenocarcinoma-bearing mice with modulation of lysosomal and ATP-ubiquitin-dependent proteolytic pathways. Int J Cancer. 1996;68:637-643.
13. Enomoto A, Rho MC, Fukami A, Hiraku O, Komiyama K, Hayashi M. Suppression of cancer cachexia by 20S,21-epoxy-resibufogenin-3-acetate-a novel nonpeptide IL-6 receptor antagonist. Biochem Biophys Res Commun. 2004;323:1096-1102.
14. Henkel T, Machleidt T, Alkalay I, Kronke M, Ben-Neriah Y, Baeuerle PA. Rapid proteolysis of IκB-α is necessary for activation of transcription factor NF-κB. Nature. 1993;365:182-185.
15. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-κB. Annu Rev Cell Biol. 1994;10:405-455.
16. Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res. 1975;35:2434-2439.
17. Tanaka Y, Eda H, Tanaka T, et al. Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice. Cancer Res. 1990;50:2290-2295.
18. Strassmann G, Jacob CO, Evans R, Beall D, Fong M. Mechanisms of experimental cancer cachexia: interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol. 1992;148:3674-3678.
19. Fujiki F, Mukaida N, Hirose K, et al. Prevention of adenocarcinoma colon 26-induced cachexia by interleukin 10 gene transfer. Cancer Res. 1997;57:94-99.
20. Yasumoto K, Mukaida N, Harada A, et al. Molecular analysis of the cytokine network involved in cachexia in colon 26 adenocarcinoma-bearing mice. Cancer Res. 1995;55:921-927.
21. Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia: local involvement of IL-1 in colon-26 tumor. J Immunol. 1993;150:2341-2345.
22. Kawamura I, Morishita R, Tomita N, et al. Intratumoral injection of oligonucleotides to the NFκB binding site inhibits cachexia in a mouse tumor model. Gene Ther. 1999;6:91-97.
23. Liu SF, Ye X, Malik AB. In vivo inhibition of nuclear factor-κB activation prevents inducible nitric oxide synthase expression and systemic hypotension in a rat model of septic shock. J Immunol. 1997;159:3976-3983.
24. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithio-carbamates as potent inhibitors of nuclear factor κB activation in intact cells. J Exp Med. 1992;175:1181-1194.
25. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation. 1999;100:1330-1337.
26. Liu SF, Ye X, Malik AB. Pyrrolidine dithiocarbamate prevents I-kB degradation and reduces microvascular injury induced by lipopolysaccharide in multiple organs. Mol Pharmacol. 1999;55:658-667.
27. Cuzzocrea S, Chatterjee PK, Mazzon E, et al. Pyrrolidine dithiocarbamate attenuates the development of acute and chronic inflammation. Br J Pharmacol. 2002;135:496-510.
28. Cuzzocrea S, Rossi A, Pisano B, et al. Pyrrolidine dithiocarbamate attenuates the development of organ failure induced by zymosan in mice. Intensive Care Med. 2003;29:2016-2025.
29. Tanaka Y, Eda H, Fujimoto K, Tanaka T, Ishikawa T, Ishitsuka H. Anticachectic activity of 5′-deoxy-5-fluorouridine in a murine tumor cachexia model, colon 26 adenocarcinoma. Cancer Res. 1990;50:4528-4532.
30. Naoe Y, Kawamura I, Inami M, et al. Anti-cachectic effect of FK317, a novel anti-cancer agent, in colon26 and LX-1 models in mice. Jpn J Cancer Res. 1998;89:1318-1325.
31. Sun J, Wang XD, Liu H, Xu JG. Ketamine suppresses endotoxin-induced NF-κB activation and cytokines production in the intestine. Acta Anaesthesiol Scand. 2004;48:317-321.
32. Liu Z, Yu Y, Jiang Y, Li J. Growth hormone increases lung NF-kappaB activation and lung microvascular injury induced by lipopolysaccharide in rats. Ann Clin Lab Sci. 2002;32:164-170.
33. Hamerman D. Molecular-based therapeutic approaches in treatment of anorexia of aging and cancer cachexia. J Gerontol A Biol Sci Med Sci. 2002;57:M511-M518.
34. Cahlin C, Korner A, Axelsson H, Wang W, Lundholm K, Svanberg E. Experimental cancer cachexia: the role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res. 2000;60:5488-5493.
35. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine. 1999;11:80-86.
36. Martignoni ME, Kunze P, Hildebrandt W, et al. Role of mononuclear cells and inflammatory cytokines in pancreatic cancer-related cachexie. Clin Cancer Res. 2005;11:5802-5808.
37. Negri DR, Mezzanzanica D, Sacco S, et al. Role of cytokines in cancer cachexia in a murine model of intracerebral injection of human tumours. Cytokine. 2001;15:27-38.
38. Samuels SE, Knowles AL, Tilignac T, Debiton E, Madelmont JC, Attaix D. Higher skeletal muscle protein synthesis and lower breakdown after chemotherapy in cachectic mice. Am J Physiol Regul Integr Comp Physiol. 2001;281:R133-R139.
39. Tisdale MJ. Loss of skeletal muscle in cancer: biochemical mechanisms. Front Biosci. 2001;6:D164-D174.
40. Tisdale MJ. Biomedicine: protein loss in cancer cachexia. Science. 2000;289:2293-2294.
41. Path G, Bornstein SR, Gurniak M, Chrousos GP, Scherbaum WA, Hauner H. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J Clin Endocrinol Metab. 2001;86:2281-2288.
42. Soda K, Kawakami M, Kashii A, Miyata M. Manifestations of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer. 1995;62:332-336.
43. Inadera H, Nagai S, Dong HY, Matsushima K. Molecular analysis of lipid-depleting factor in a colon-26-inoculated cancer cachexia model. Int J Cancer. 2002;101:37-45.